pravastatin / Generic mfg. - LARVOL DELTA

EFFECTIVENESS OF STATIN THERAPY FOR ELEVATED LIPID LEVELS IN PATIENTS ON MTOR INHIBITORS AFTER HEART TRANSPLANTATION (WRMC 2026) - "Randomized control trials have demonstrated that one therapeutic strategy to slow the progression of CAV is the use of mTOR inhibitors (mTORi), including sirolimus and everolimus...Methods Used: Between 2010 to 2024, we assessed 41 HTx recipients who were transitioned from pravastatin, a low potency statin, to a high potency statin, specifically rosuvastatin or atorvastatin, after initiating mTORi therapy... Switching patients to high potency statin therapy effectively lowered lipid levels in heart transplant recipients on mTORis. Statin intensification (select dosing) appears safe and well tolerated in this population."

Clinical • Cardiovascular • Dyslipidemia • Metabolic Disorders • Transplantation

Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes. (PubMed, Hepatology) - "Mitochondrial and metabolic dysregulation are central to the pathogenesis of PLD. Targeting cholesterol metabolism with statins represents a promising therapeutic strategy to slow disease progression and reduce cyst burden."

Journal • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Transplantation

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. (PubMed, Lancet) - "Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) listed in product labels as potential undesirable effects. In light of these findings, such labelling and other official sources of health information should be revised so that patients and their doctors can make appropriately informed decisions regarding statin therapy."

Adverse events • Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Diabetes • Metabolic Disorders • Pain • Psychiatry • Sleep Disorder

Repurposing Pravastatin and Metformin for the Treatment and Prevention of Noise-Induced Hidden Hearing Loss in a Mouse Model (ARO 2026) - "ABR and DPOAE thresholds were assessed using two-way ANOVA with Tukey’s multiple comparisons, and wave-I amplitudes with two-way ANOVA followed by Dunnett’s test versus placebo; adjusted p values are reported. After completion with an expanded sample size across sexes, our data demonstrate that metformin plus pravastatin improves early auditory recovery after acoustic trauma. Effects were frequency- and sex-dependent, with combination therapy providing the most consistent protection in males and pravastatin contributing in females. Ongoing histology will clarify synaptic preservation underlying these outcomes and will be presented at February 2026 meeting."

Preclinical • Mood Disorders • Otorhinolaryngology • CTBP2

The many faces of cholesterol in autosomal dominant polycystic kidney disease. (PubMed, Kidney Int) - "The pravastatin clinical trial by Gitomer et al...Emergence of novel lipid-lowering therapies presents new therapeutic opportunities but also risks. Recent studies suggest that cholesterol is important for traffic to and function of polycystins in primary cilia."

Journal • Review • Autosomal Dominant Polycystic Kidney Disease • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Ferritin-Based Pravastatin Assembly Augments Mucus Penetration and Ameliorates Acute Lung Injury Via Rho/ROCK Signaling Pathway. (PubMed, Macromol Biosci) - "In vitro and in vivo investigations revealed that Prv@FTn alleviates LPS-induced ALI symptoms through inhibition of the Rho-ROCK I/II signaling pathway. These findings suggest that mucus-penetrating Prv@FTn is a promising Rho/ROCK signaling pathway inhibitor for ALI therapy."

Journal • Acute Lung Injury • Inflammation • Respiratory Diseases

Pravastatin combined with fibrin sealant-embedded BMSCs enhances recovery in steroid-induced avascular necrosis of the femoral head. (PubMed, Sci Rep) - "Group D showed significantly lower serum lipid content and femoral head necrosis than other groups, with HE staining revealing fewer empty lacunae and increased trabecular bone density. Additionally, VEGF expression was markedly elevated in Group D. These findings indicate that BMSCs embedded in biomaterials enhance the therapeutic efficacy for early SANFH, and the combination with pravastatin significantly improves outcomes, suggesting a promising new approach for clinical management of femoral head necrosis."

Journal

Analytical Techniques for the Quantification of Pravastatin and Its Metabolites in Various Matrices: A Comprehensive Review. (PubMed, Biomed Chromatogr) - "The literature demonstrates that liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography remain the most sensitive and reliable platforms for ultratrace bioanalysis, while spectrophotometric and electrochemical methods provide cost-effective alternatives for formulations and higher concentration samples, and capillary electrophoresis offers efficient separation with low solvent use. Future analytical advances should prioritize metabolite-resolved quantification, green extraction strategies, microfluidic and point-of-care designs, and AI-assisted data processing to improve sensitivity, stability assessment, and high-throughput monitoring of PRV in clinical and environmental settings."

Journal • Review • Cardiovascular • Dyslipidemia • Metabolic Disorders

PROBUCOL HALVES ALL-CAUSE DEMENTIA RISK: EVIDENCE FROM A NATIONWIDE COHORT (ADPD 2026) - P2 | "Protective associations were consistent across individual statins, most pronounced versus pravastatin (aOR = 0.31, 95% CI: 0.24–0.38) and pitavastatin (aOR = 0.30, 95% CI: 0.24–0.38). Conclusions Probucol use was associated with significant lower odds of dementia, with robust effects across statin comparators. These findings highlight the translational potential of targeting peripheral amyloid–capillary interactions. Confirmation in the ongoing Probucol in Alzheimer's Study (ACTRN12621000726853) could provide a compelling rationale for scalable and cost-effective adoption of probucol in dementia prevention and treatment."

Alzheimer's Disease • CNS Disorders • Dementia • Inflammation

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells. (PubMed, PLoS One) - "To investigate this, we synthesized statin-dye conjugates by attaching a fluorescent dye (Cy5.5) to two statins: simvastatin and pravastatin, aiming to assess whether selective uptake indeed occurs. Notably, in the PCC and CAF co-culture model, the pravastatin-Cy5.5 conjugate selectively killed KRASMUT PCCs without affecting the KRASWT CAFs. These findings highlight the unique synergistic potential of statin-Cy5.5-distinct from either component alone-as targeted delivery vehicles for KRASMUT cancer therapy."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CAFs • KRAS • PTEN

Qingdu Wenxin Formula mitigates doxorubicin-induced cardiotoxicity via inhibition of cGAS/STING/NF-κB pathway-mediated inflammation (PubMed, Zhongguo Zhong Yao Za Zhi) - "C57BL/6J mice were randomized into control, model, pravastatin(40 mg·kg~(-1)), and low-(1.3 g·kg~(-1)), medium-(2.6 g·kg~(-1)), and high-dose(5.2 g·kg~(-1)) QD-WXF groups. In the experiment with STING~(KO), there was no significant difference between the QD-WXF group and the model group, while significant differences existed between the WT model group and the STING~(KO) model group. The above results indicate that QD-WXF can effectively alleviate doxorubicin-induced cardiotoxicity by inhibiting the inflammation via the cGAS/STING/NF-κB pathway."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • Oncology • IL1B • IL6 • STING • TNFA

IMPROVE-FALD: IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Children's Mercy Hospital Kansas City | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hepatology

Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®. (PubMed, Ther Innov Regul Sci) - "A new user cohort design was employed in which patients prescribed one of six statins (atorvastatin, simvastatin, pitavastatin, pravastatin, fluvastatin, or rosuvastatin) in Japan between January 1, 2014 and March 31, 2022 were identified in the MID-NET® database. Results suggest that risks of liver dysfunction by generic statins are similar to those for brand drugs, facilitating our understanding about the safety of generic drugs. The aHR for atorvastatin was inconsistent between the primary and additional analyses, which suggests that the observed increased risk of generic atorvastatin may be affected by other factors and does not necessarily indicate a different safety profile between generic and brand drugs."

Journal • Hepatology • Liver Failure

Drug Development. (PubMed, Alzheimers Dement) - "Our findings suggest that rosuvastatin may be superior to other statins in reducing the risk of ADRD."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Psychiatry

Lipid dysregulation after hematopoietic stem cell transplant. (PubMed, Haematologica) - "Addition of ceramide levels to ST2 only modestly improved prediction of later TA-TMA in ROC analysis. Pravastatin prophylaxis was associated with distinct shifts in lipoprotein and ceramide profiles, potentially reflecting modulation of endothelial function.Pravastatin may alter ceramide and lipoprotein pathways in a clinically meaningful way, contributing to their role in endothelial protection."

Journal • Bone Marrow Transplantation • Pediatrics • Transplantation

Suspected S-1-Induced Rhabdomyolysis during Adjuvant Chemotherapy after Breast Cancer Surgery-A Case Report (PubMed, Gan To Kagaku Ryoho) - "We present a case of suspected S-1-induced rhabdomyolysis in a 56-year-old woman with a history of hypertension and dyslipidemia, who was taking amlodipine besilate and pravastatin sodium...Following dose-dense EC therapy and discontinuation of docetaxel owing to drug-induced pneumonitis, she began adjuvant therapy with letrozole and S-1...Given the temporal relationship and resolution upon drug withdrawal, S-1 was considered the likely causative agent. Although extremely rare, clinicians should be aware of the potential for S-1-induced rhabdomyolysis and monitor for muscle-related symptoms during treatment."

Journal • Breast Cancer • Cardiovascular • Dyslipidemia • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Oncology • Pain • Pneumonia • Solid Tumor • HER-2

Pravastatin to Prevent Preeclampsia (clinicaltrials.gov) - P3 | N=102 | Terminated | Sponsor: The George Washington University Biostatistics Center | N=50 ➔ 102

Enrollment change • Cardiovascular • Gynecology • Hypertension • Obstetrics

Systematic metabolic engineering of an industrial Penicillium citrinum for one-step pravastatin production. (PubMed, Metab Eng) - "This work established a one-step fermentation process for pravastatin production with markedly improved efficiency over the conventional methods. This work not only establishes an efficient, green production route for pravastatin but also provides a versatile engineering framework for the sustainable biosynthesis of other complex fungal polyketides."

Journal

Molecular MRI of Collagen Enables Evaluation of Fibrosis and Therapeutic Response in Venous Thrombosis. (PubMed, Circ Cardiovasc Imaging) - "A subgroup of mice with DVT (n=7) was treated with pravastatin in drinking water (40 mg/kg per d) for 3 weeks post-DVT...Statin treatment decreased both collagen accumulation and vein wall thickness, without affecting thrombus size. Molecular MRI using a collagen-targeting probe made collagenous thrombus visible on MRI and detected changes in collagen content during thrombus resolution."

Journal • Cardiovascular • Fibrosis • Hematological Disorders • Immunology • Thrombosis

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance. (PubMed, J Nanobiotechnology) - "Here, we develop Fe/CDP, a nanoparticle with a Fe3O4 core coated with chondroitin sulfate and loaded with pravastatin, a mevalonate pathway inhibitor, and doxorubicin (DOX). Moreover, cholesterol depletion facilitates lipid peroxidation, synergizing with Fe3O4 to trigger ferroptosis through CoQ10/GPX4/FSP1 downregulation. By eliminating both bulk tumor cells and CSCs, Fe/CDP provides a cholesterol-modulating strategy to overcome TNBC drug resistance."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AIFM2 • ALDH1A1 • EGFR • GPX4

Pravastatin and L-Arginine Use in Early-Onset Severely Growth-Restricted Dichorionic Twins: A Case Report. (PubMed, Am J Case Rep) - "This report supports findings from recent studies that combined pravastatin and L-arginine can improve fetal development and survival in FGR within monochorionic twin pregnancies. Adequately powered and randomized trials are needed to confirm this finding."

Journal • Gynecology

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability-Limited Multicompartment Liver Model. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Systemic and hepatocellular concentrations of pravastatin, rosuvastatin, and atorvastatin were simulated in Healthy Volunteers (HV), Obese, Morbidly Obese, and MASH virtual populations with the Simcyp Simulator. In MASH, unbound hepatocellular exposure increased by up to 127% in the periportal region for atorvastatin and decreased by up to 55% in the pericentral region for rosuvastatin. The pharmacodynamic model simulated decreased rosuvastatin cholesterol-lowering efficacy in MASH compared with Obese, which could be compensated for with a 50% increase in dose according to exploratory simulations."

Journal • PK/PD data • Dyslipidemia • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial. (PubMed, Trials) - "The results of this study are expected to have wide-ranging implications given the effects of hypertensive disorders of pregnancy on long-term maternal and child health, as well as health economics."

Journal • Cardiovascular • Critical care • Gynecology • Hematological Disorders • Hypertension • Renal Disease • Small for Gestational Age • Thrombocytopenia • FLT1